COMMUNIQUÉS West-GlobeNewswire

U.S. Government Awards BioCryst $69 Million RAPIVAB® (peramivir injection) Contract for Strategic National Stockpile

30/09/2024 - 13:00

RESEARCH TRIANGLE PARK, N.C., Sept. 30, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the U.S. Department of Health and Human Services (HHS) has awarded BioCryst up to a $69 [...]

Akero Therapeutics to Present at the H.C. Wainwright 8th Annual MASH Virtual Conference

30/09/2024 - 13:00

SOUTH SAN FRANCISCO, Calif., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases [...]

Walden Biosciences Fully Enrolls First Cohort in Phase 2 Basket Study of WAL0921 in Chronic Kidney Diseases

30/09/2024 - 13:00

Expects Topline Results from First Multiple Ascending Dose Cohort by Year-end 2024 and to Initiate Rare Kidney Disease Cohorts in Early 2025 CAMBRIDGE, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Walden Biosciences, Inc [...]

Nurix Therapeutics Announces Presentations at Discovery on Target Conference

30/09/2024 - 13:00

SAN FRANCISCO, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer [...]

BioStem Technologies, Inc. Files Form 10 with the Securities and Exchange Commission and Submits Nasdaq Application for Uplisting

30/09/2024 - 13:00

Nasdaq listing aims to increase market visibility and global liquidity opportunities as BioStem advances its commercial and clinical initiatives amid record revenue growth POMPANO BEACH, Fla., Sept. 30, 2024 (GLOBE [...]

CytoMed Therapeutics Reports Six Months Ended June 30, 2024 Financial Results and Provides Clinical and Corporate Updates

30/09/2024 - 13:00

Conference call via Zoom is scheduled for October 8, 2024 at 9 a.m. ET (9 p.m. SGT) https://us06web.zoom.us/meeting/register/tZMrcOmppj0sGdA37lASywTyixRflo9w1TZT SINGAPORE, Sept. 30, 2024 (GLOBE NEWSWIRE) -- CytoMed [...]

Prime Medicine Announces Strategic Research Collaboration and License Agreement with Bristol Myers Squibb to Develop and Commercialize Multiple Prime Edited Ex Vivo T-Cell Therapies

30/09/2024 - 13:00

Collaboration Combines Prime Medicine’s Precise, Multiplex Gene Editing Capabilities with Bristol Myers Squibb’s Broad Expertise in Development and Commercialization of Novel Cell Therapies Prime Medicine to Receive $ [...]

Dr. Robert Langer, Co-Founder of Moderna, Joins Scientific Advisory Board of Klotho Neurosciences, Inc. (KLTO)

30/09/2024 - 12:00

Renowned Biotech Leader to Contribute Expertise in Neuroscience and Therapeutics Development NEW YORK, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Klotho Neurosciences, Inc. (NASDAQ: KLTO), a cutting-edge biotechnology company [...]

More Adults With Type 1 Diabetes Achieved A1C Goal (<7%) After Switching From Multiple Daily Insulin Injections or Automated Pumps to Inhaled Insulin (Afrezza®)

30/09/2024 - 12:00

30-week results from the Phase 4 INHALE-3 study expand upon the positive 17-week data presented earlier this year at the American Diabetes Association’s 84 th Scientific Sessions Switching to, or remaining on Afrezza [...]

European Commission approves Yuvanci® (Single Tablet Combination Therapy [STCT] of Macitentan and Tadalafil) for Treatment of Patients with Pulmonary Arterial Hypertension (PAH)

30/09/2024 - 10:58

With this approval, Yuvanci ® is the only single tablet combination therapy for treatment for patients with PAH in Europe Johnson & Johnson’s comprehensive PAH portfolio now covers all three guideline-recommended [...]

Tessellate BIO, Omico and CMRI announce a multi-year collaboration to accelerate discovery of synthetic lethal precision therapies to address ‘ALT’ cancers

30/09/2024 - 09:43

AMSTERDAM and SYDNEY, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Tessellate BIO, a preclinical stage biotechnology company with a focus on novel Synthetic Lethality approaches, announces a collaboration with CMRI, a leading [...]

Orion’s near-term climate targets approved by the Science Based Targets initiative

30/09/2024 - 09:00

ORION CORPORATION PRESS RELEASE 30 SEPTEMBER 2024 at 10.00 a.m. EEST Orion’s near-term climate targets approved by the Science Based Targets initiative Orion Corporation is proud to announce that the Science Based [...]

AB Science annonce une augmentation de capital de 5,0 millions d’euros

30/09/2024 - 08:29

COMMUNIQUE DE PRESSE REALISATION AVEC SUCCES D’UNE AUGMENTATION DE CAPITAL PAR PLACEMENT PRIVE POUR UN MONTANT DE 5 MILLIONS D’EUROS Paris, 30 septembre 2024, 8h30 AB Science S.A. (la « Société » ou « AB Science », [...]

BioSenic announces that it has started to look for new assets, the securing of its financing for the coming months by means of an amendment to its convertible bond contract, a change to the composition of its board of directors

30/09/2024 - 08:05

PRIVILEGED INFORMATION Biosenic and Global Tech Opportunities 15 ("GTO 15") have entered into an amendment to the convertible bonds ("CB") agreement securing a further EUR 1.5 million of the programme, including at [...]

BioSenic annonce démarrer la recherche de nouveaux actifs, la sécurisation de son financement pour les prochains mois par le biais d'un avenant à son contrat d'obligations convertibles, une modification de la composition de son conseil

30/09/2024 - 08:05

INFORMATION PRIVILIGIEE Biosenic et Global Tech Opportunities 15 ("GTO 15") ont conclu un avenant à la convention obligations convertibles ("OC") sécurisant encore 1,5 million EUR sur le programme dont à tout le moins [...]

Verona Pharma to Present Six Analyses of the Phase 3 ENHANCE Studies in COPD at CHEST 2024

30/09/2024 - 08:00

Data support Ohtuvayre™ (ensifentrine), as a first-in-class, selective, dual inhibitor of PDE3 and PDE4 in a broad COPD population LONDON and RALEIGH, N.C., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: [...]

BioSenic reports half year 2024 results

30/09/2024 - 07:00

REGULATED INFORMATION The interim financial report is prepared in accordance with article 13 of the Royal Decree on the obligations of issuers of financial instruments admitted to trading on a regulated market and can [...]

BioSenic publie ses résultats pour le premier semestre 2024

30/09/2024 - 07:00

INFORMATION REGLEMENTEE Le rapport semestriel est préparé conformément à l’article 13 de l’Arrêté Royal relatif aux obligations des émetteurs d’instruments financiers admis à la négociation sur un marché réglementé et [...]

Addex Therapeutics Reports 2024 Half Year and Second Quarter Financial Results and Provides Corporate Update

30/09/2024 - 07:00

Launched Neurosterix with Perceptive Advisors to accelerate the development of M4PAM for schizophrenia Indivior selected GABA B PAM drug candidate for development in substance use disorders Addex selected independent [...]